FONT-SIZE Plus   Neg

GE Healthcare Reveals Phase 3 Results For Imaging Agent Flutemetamol

GE Healthcare, a unit of diversified conglomerate General Electric Co. (GE), Wednesday released results from four pooled brain biopsy studies and results from a brain autopsy study of the investigational PET amyloid imaging agent, flutemetamol.

The results revealed that both biopsy and autopsy study images had high sensitivity and specificity, and that strong concordance exists between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

The data confirm the potential of flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease in living patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Visa Inc. (V) on Monday reported an increase in profit for the fourth quarter, as revenues jumped driven largely by increase in customer spending and inclusion of Europe business. Earnings and revenues trumped Wall Street expectations. Foster City, California-based Visa's fourth-quarter profit rose... As Sony Corp. prepares to launch the new PlayStation 4 Pro gaming console on November 10, several new games that are compatible with the console have also been confirmed for launch. Game developers are readying to provide PlayStation 4 Pro support for many games on PS4. Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
comments powered by Disqus
Follow RTT